PRME Prime Medicine
- 5.820
- +0.210+3.74%
Prime Medicine News
Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Shares of Aspen Aerogels, Inc. (NYSE:ASPN) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results.Aspen Aerogels posted a GAAP loss
Prime Medicine to Participate in the 27th Annual Milken Institute Global Conference
PDF Version CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curati
FDA Clears Prime Medicine to Begin Gene Therapy Clinical Testing
Prime Medicine Shares Rise 13% After FDA Clears IND Application
By Chris Wack Prime Medicine shares were up 13%, to $5, after the company said that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for PM359 for the treatm
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister it
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Nasdaq Composite jumping over 50 points on Monday.Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply during Monday's session on reports the company will partner with Ba
Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance
Prime Medicine (PRME) shares rose 8.5% in recent trading after the company said Monday that its investigational new drug application for potential treatment of chronic granulomatous disease received c
Prime Medicine Shares Are Trading Higher on FDA Clearance of Its IND Application for PM359.
Prime Medicine Shares Are Trading Higher on FDA Clearance of Its IND Application for PM359.
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
PDF Version First-Ever Open IND for Prime Editing TechnologyPM359 is Prime Medicine's Ex Vivo Product Candidate Designed to Correct a Prevalent Disease-Causing Mutation of CGDInitial Data Expecte
Buy Rating Affirmed for Prime Medicine, Inc. on Strong Preclinical Data and Promising Clinical Outlook
Prime Medicine Price Target Maintained With a $12.00/Share by Wedbush
Prime Medicine Price Target Maintained With a $12.00/Share by Wedbush
Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
Wedbush: Reiterates Prime Medicine's (PRME.US) rating and adjusted from superior to superior market rating, with a target price of $12.00.
Wedbush Reiterates Outperform on Prime Medicine, Maintains $12 Price Target
Wedbush analyst David Nierengarten reiterates Prime Medicine (NASDAQ:PRME) with a Outperform and maintains $12 price target.
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific Meetings
PDF Version -- Presentations include new preclinical data for PM359, further demonstrating ability of Prime Editors to efficiently, reproducibly and durably correct causative mutation of CGD; on
Prime Medicine Initiated at Buy by Chardan Capital
Prime Medicine Initiated at Buy by Chardan Capital
Buy Rating Affirmed for Prime Medicine, Inc. on Groundbreaking Genetic Editing Platform and Strategic Progress
Prime Medicine (PRME.US) was first covered by Chardan Capital, giving it a buy rating, with a target price of $17.00.
Prime Medicine (PRME.US) was first covered by Chardan Capital, giving it a buy rating, with a target price of $17.00.
Chardan Capital Initiates Coverage On Prime Medicine With Buy Rating, Announces Price Target of $17
Chardan Capital analyst Geulah Livshits initiates coverage on Prime Medicine (NASDAQ:PRME) with a Buy rating and announces Price Target of $17.
Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN)
Prime Medicine Initiated at Buy by TD Cowen
Prime Medicine Initiated at Buy by TD Cowen
Analysis
Price Target
No Data
